Leukocyte adherence inhibition and immunoreactivity in prostatic cancer. II. Tissue- and disease-specificity of anti-tumour cell-mediated immunity

Tissue- and disease-specificity of the reactivity of peripheral blood leukocytes from 20 prostatic cancer patients to malignant prostatic tissue have been evaluated. Results of leukocyte adherence inhibition, employed previously, had suggested antitumour cell-mediated immunity. Absence of significant reactivity in prostatic cancer patients to tissues other than malignant prostate and in non-prostatic cancer patients (including patients with benign disease of the prostate) to malignant prostate confirms earlier observations. These had suggested the identification of prostatic tumour-associated antigens and of tumour-associated immunity in prostatic carcinoma.